185 related articles for article (PubMed ID: 11329288)
1. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
2. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
3. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
Baldwin J; Farajallah AM; Malmquist NA; Rathod PK; Phillips MA
J Biol Chem; 2002 Nov; 277(44):41827-34. PubMed ID: 12189151
[TBL] [Abstract][Full Text] [Related]
4. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
5. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
[TBL] [Abstract][Full Text] [Related]
6. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites.
Walse B; Dufe VT; Svensson B; Fritzson I; Dahlberg L; Khairoullina A; Wellmar U; Al-Karadaghi S
Biochemistry; 2008 Aug; 47(34):8929-36. PubMed ID: 18672895
[TBL] [Abstract][Full Text] [Related]
7. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Liu S; Neidhardt EA; Grossman TH; Ocain T; Clardy J
Structure; 2000 Jan; 8(1):25-33. PubMed ID: 10673429
[TBL] [Abstract][Full Text] [Related]
8. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.
Hansen M; Le Nours J; Johansson E; Antal T; Ullrich A; Löffler M; Larsen S
Protein Sci; 2004 Apr; 13(4):1031-42. PubMed ID: 15044733
[TBL] [Abstract][Full Text] [Related]
12. Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression.
Neidhardt EA; Punreddy SR; McLean JE; Hedstrom L; Grossman TH
J Mol Microbiol Biotechnol; 1999 Aug; 1(1):183-8. PubMed ID: 10941801
[TBL] [Abstract][Full Text] [Related]
13. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
Jöckel J; Wendt B; Löffler M
Biochem Pharmacol; 1998 Oct; 56(8):1053-60. PubMed ID: 9776318
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
Kim TH; Na HS; Löffler M
Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
[TBL] [Abstract][Full Text] [Related]
18. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Moss D; Thomson TA; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E
J Biol Chem; 1995 Sep; 270(38):22467-72. PubMed ID: 7673235
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
20. A second dihydroorotate dehydrogenase (Type A) of the human pathogen Enterococcus faecalis: expression, purification, and steady-state kinetic mechanism.
Marcinkeviciene J; Jiang W; Locke G; Kopcho LM; Rogers MJ; Copeland RA
Arch Biochem Biophys; 2000 May; 377(1):178-86. PubMed ID: 10775458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
